Aligos Therapeutics, Inc.
ALGS
$10.01
$0.141.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -23.21% | 210.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.21% | 210.29% | |||
| Cost of Revenue | 71.27% | -3.63% | |||
| Gross Profit | -78.28% | 8.32% | |||
| SG&A Expenses | -7.04% | 9.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 49.00% | -0.11% | |||
| Operating Income | -52.75% | 3.51% | |||
| Income Before Tax | -100.80% | -136.35% | |||
| Income Tax Expenses | -69.73% | 330.23% | |||
| Earnings from Continuing Operations | -98.81% | -136.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -98.81% | -136.82% | |||
| EBIT | -52.75% | 3.51% | |||
| EBITDA | -53.71% | 3.89% | |||
| EPS Basic | -98.45% | -129.91% | |||
| Normalized Basic EPS | -100.44% | -129.53% | |||
| EPS Diluted | -98.45% | 27.37% | |||
| Normalized Diluted EPS | -100.44% | -130.58% | |||
| Average Basic Shares Outstanding | 0.18% | 23.10% | |||
| Average Diluted Shares Outstanding | 0.18% | 18.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||